ibandronate vs risedronate
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of ibandronate and risedronate. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Boniva
Actonel
Ibandronate (Boniva) is a medicine that helps treat and prevent bone loss in women after menopause. It makes bones stronger and less likely to break.
Risedronate sodium delayed-release tablets help treat osteoporosis after menopause. It helps to make your bones stronger and less likely to break.
Ibandronate is used to treat and prevent osteoporosis in women after menopause. Osteoporosis is a condition that makes bones weak and more likely to break. This medicine helps to increase bone strength and reduce the chance of fractures, especially in the spine.
This medicine treats osteoporosis in women after menopause. Osteoporosis makes bones weak and more likely to break. Risedronate can lower the chance of breaks in the spine and other bones.
Ibandronate belongs to a class of drugs called bisphosphonates. It works by slowing down the breakdown of bone. This helps to increase bone density and reduce the risk of fractures.
Risedronate belongs to a class of drugs called bisphosphonates. It works by slowing down the breakdown of bone. This helps to increase bone density and reduce the risk of fractures.
- • Back pain
- • Upset stomach
- • Pain in arms or legs
- • Diarrhea
- • Headache
- • Diarrhea
- • Flu-like symptoms
- • Joint pain
- • Back pain
- • Abdominal pain
- Arthralgia 243
- Diarrhoea 230
- Nausea 219
- Femur Fracture 216
- Headache 198
- Arthralgia 3,730
- Pain 3,613
- Nausea 2,991
- Fatigue 2,911
- Dyspnoea 2,802
This medicine can cause problems with your esophagus. To help prevent this, follow the directions carefully and stay upright for at least 60 minutes after taking it. Rarely, serious bone, joint, or muscle pain can occur. Tell your doctor if you have new pain in your thigh or groin. Osteonecrosis of the jaw (bone damage in the jaw) has been reported.
Risedronate can cause problems with your esophagus. Follow the directions carefully and stay upright for 30 minutes after taking it. It can also cause bone, joint, or muscle pain. Tell your doctor right away if you have new pain in your thigh or groin.
Ibandronate is not for use in women who can get pregnant. It is not known if this medicine will harm an unborn baby. Talk to your doctor if you are breastfeeding.
Stop taking risedronate if you become pregnant. This medicine can affect the baby's bones. It is not known if risedronate passes into breast milk.
Also Compare, Nearby Drugs
Compare ibandronate with
Compare risedronate with
How to Read This ibandronate vs risedronate Comparison
ibandronate is classified in the Bisphosphonate drug class, while risedronate sits within the Bisphosphonate class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, ibandronate has 1,106 submissions while risedronate has 16,047. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for ibandronate or risedronate.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.